Understanding the andromeda strain - The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness.
Blood Rev
; 45: 100731, 2021 01.
Article
in English
| MEDLINE | ID: covidwho-628730
ABSTRACT
As the current coronavirus pandemic continues and cases of COVID-19 critical illness rise, physicians and scientists across the globe are working to understand and study its pathophysiology. Part of the pathology of this illness may result from its prothrombotic potential as witnessed from derangements in coagulation and thrombotic complications reported in observational studies performed in China and Europe to findings of microthrombosis upon autopsy analysis of patients who succumbed to COVID-19. Multiple organizations, including the American Society of Hematology (ASH), recommend the routine use of prophylactic heparin to temper the thrombotic complications of this illness given its mortality benefit in severe COVID-19 infections. Reductions in circulating levels of Antithrombin III (AT), the primary mediator of heparin's action, is present in cases of coronavirus related critical illness. AT's use as a prognostic marker, an important effector of heparin resistance, and a potential therapeutic target for COVID-19 remains to be explored.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antithrombin III
/
Disseminated Intravascular Coagulation
/
Venous Thromboembolism
/
Cytokine Release Syndrome
/
SARS-CoV-2
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Blood Rev
Journal subject:
Hematology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS